On Oct. 5, 2020, Bristol-Myers and MyoKardia announced a definitive merger agreement under which Bristol Myers Squibb will acquire MyoKardia for $13.1 billion, or $225.00 per share in cash. The transaction was unanimously approved by both the Bristol Myers Squibb and MyoKardia Boards of Directors and was anticipated to close during the fourth quarter of 2020.